When Irish biotech firm Elan Corp. launched Tysabri to treat multiple sclerosis and other autoimmune diseases, the new drug was 50 percent more effective than any other treatment of MS.It fed a desire in Nancy Bryan at the time an executive at Elan to make a difference in the lives of patients.Bryan heard patients stories, including one from a woman who could walk her daughter down the aisle ...
More...